In 2010, we entered into a collaboration agreement with Takeda to develop and commercialize NB-32 in the United States, Canada and Mexico. We have received $50.0 million from Takeda and we are eligible to receive additional payments of over $1.0 billion upon achieving certain milestones, including $100.0 million that can be achieved between the approval and the first commercial sale of NB-32 in the United States. The collaboration agreement provides that Takeda will be responsible for commercialization costs and activities.
We are considering potential partnership opportunities for Empatic as well as NB-32 outside of the United States, Canada and Mexico.
For more information about Takeda, visit: www.takeda.com